In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BI gets BACE1 inhibitors from Vitae in their second alliance; terminated

Executive Summary

Less than two years after they partnered on 11beta-HSD1-targeting drug candidates for metabolic diseases, Vitae Pharmaceuticals (small-molecule drug discovery) and Boehringer Ingelheim are teaming up again, this time to jointly identify beta-secretase (beta-site APP cleaving enzyme 1 or BACE1) inhibitors for Alzheimer's disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies